This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Positive Results Presented From Proof-of-Concept Phase II Clinical Trial Of Incyte’s Oral JAK1 Inhibitor In Patients With Active Rheumatoid Arthritis

Incyte Corporation (Nasdaq: INCY) announced results from a 12-week, placebo-controlled, dose-escalation Phase II proof-of-concept clinical trial involving 60 patients with active rheumatoid arthritis for its proprietary oral JAK1 inhibitor. These results were presented today at the 2013 American College of Rheumatology / Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting being held in San Diego, CA, from Oct. 25 to 30, 2013.

“Along with our recently presented data with INCB39110 in psoriasis, results from this study in rheumatoid arthritis demonstrate the potential of JAK1 inhibition in inflammatory indications,” stated Richard S. Levy, Incyte’s Executive Vice President and Chief Drug Development and Medical Officer.

In this initial Phase II trial, 12 weeks of treatment with INCB39110 showed efficacy at all doses as measured by ACR 20, ACR 50, ACR 70, and DAS 28 as compared to placebo. Clinical benefit was observed as early as one week of treatment, and the highest dose tested, once-daily 600 mg, appeared to be the most effective dose. Below is a summary of the key efficacy endpoints evaluated at 12 weeks:

Placebo N=12

100 mg BID N=13

300 mg QD N=12

200 mg BID N=13

600 mg QD N=11
ACR 20, n (%)       4 (33)       7 (54)       6 (50)       6 (46)       10 (91)
ACR 50, n (%)       2 (17)       6 (46)       5 (42)       5 (39)       7 (64)
ACR 70, n (%)       1 (8)       4 (31)       1 (8)       2 (15)       6 (55)

Placebo N=12

100 mg BID N=13

300 mg QD N=12

200 mg BID N=13

600 mg QD N=11

Mean score*
      5.4 (–1.2)       4.0 (–2.7)       3.9 (–2.5)       4.3 (–2.4)       3.1 (–3.2)
DAS 28 ESR< 2.6, n (%)       0 (0)       1 (8)       2 (17)       3 (23)       3 (27)

Mean score*
      4.8 (–1.1)       3.3 (–2.7)       3.2 (–2.4)       3.6 (–2.2)       2.7 (–2.9)
DAS 28 CRP< 2.6, n (%)       0 (0)       4 (31)       3 (25)       2 (15)       5 (46)

* Mean score at week 12 (change from baseline)


While larger patient populations and longer term exposure are needed to fully explore the safety profile of INCB39110, at all doses evaluated in this trial, the compound was generally well-tolerated without evidence of myelosuppression or immunosuppression. Additionally, all treatment-emergent AEs were mild to moderate in intensity; there were no drug related serious adverse events, and no serious related or unrelated infections. Mean values for evaluated safety measures, including hemoglobin, neutrophil count, platelet count and lymphocyte count, remained stable and within normal range across the 12 weeks of the study. Mild increases were observed in ALT and AST during the first weeks of treatment. No patient developed a Grade 3 or Grade 4 abnormality or had an associated increase in bilirubin, which is consistent with enzyme induction. Increases in LDL and HDL were also noted, consistent with the expected effects of reduction of IL-6 signaling, without a significant change in the HDL/LDL ratio.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%
TSLA $247.54 -0.07%
YHOO $36.59 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs